Anything is possible, but what makes DARA such a great value is it has 3 licensing deals that could generate significant revenues if they decide to-- but they have made no mention that additional revenue is needed for current operations. Value alone 5x the the current market cap. I have very little doubt DARA is just completely off the radar of most investors and analysts. The most exciting aspect of the company however, is its neuropathy drug-- which has already had a positive 2a trial. Low risk, extremely high reward-- that is the type of company I like to invest in.